MRKBy Calypso Research8 min read

Merck & Co. (MRK) Q4 2025 Earnings Analysis

Keytruda's Cliffhanger: Merck's $16.4B Balancing Act

Key Takeaways

Merck & Co. (MRK) reported Q4 2025 earnings with revenue of $16.4B, representing a +5.0% year-over-year change. The stock moved +2.2% on earnings day.

The bull case: A broadened, increasingly de-risked pipeline across oncology, cardiometabolic, infectious disease, HIV, immunology, and ophthalmology, combined with disciplined but active BD, enables Merck to offset KEYTRUDA LOE and sustain mid-single-digit or better growth into the 2030s.

The bear case: Despite a large stated $70B opportunity, Merck faces a period of muted reported growth, major LOE and IRA headwinds, intense competition in key pipeline categories, and potential pressure to pursue large acquisitions that could dilute returns and heighten execution risk.

Financial Highlights

  • Revenue: $16.4B (+5.0% YoY)
  • Gross Profit: $15.2B (92.7% margin, +17.2% YoY)
  • Operating Income: $8.7B (53.3% margin, +25.4% YoY)
  • Net Income: $3.0B
  • TTM Revenue: $65.0B

Stock Performance

  • Earnings Day Move: +2.2%
  • Year-to-Date: +16.3%
  • 1-Year Return: +35.7%
  • vs. S&P 500 (since earnings): +35.5%
  • vs. Nasdaq (since earnings): +38.4%

View live MRK data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Merck & Co.'s Q4 2025 earnings call:

Durability of KEYTRUDA’s IP/LOE and Role of QLEX in Managing the Cliff

Sentiment: Positive

"One of those is the compound patent, which expires December 2028. Two of those, one in method of making patent, actually is extended out to May 2029, and the second one, a method of use patent goes out to November 2029... our confidence that we will be able to defend those additional two patents has grown." — Robert M. Davis
"As we think about the QLEX adoption, we continue to think we are going to see 30% to 40% adopted as you get out to 2028... and frankly, whether it is '28 or '29 does not change the strategy we are following." — Robert M. Davis

Long‑Term Growth Algorithm vs. Near‑Term “Minimal” Top‑Line Growth and LOE Drag

Sentiment: Positive

"I am not sure I agree with your characterization that we will be a modest growing company in every year... if you look over the longer term, that $70 billion we have of potential is significant... and important $20 billion higher than where we were and driven by probably the broadest and widest pipeline we have had in here." — Robert M. Davis
"If you adjust for the LOE period we had... we actually are giving guidance of growth in, I think, the 4% to 7% or roughly 5% to 8% range over time, which actually is pretty strong growth... What is the sustainable strategic growth of those assets long term, not what are the one-time nonstrategic LOEs we are facing this year." — Robert M. Davis

MK1406 (Sidera) Flu Antiviral – Trial Design, Interim Analysis, and Magnitude of Opportunity

Sentiment: Positive

"We have completed enrollment in the Northern Hemisphere... we are in parallel recruiting in the Southern Hemisphere. This is an event-driven trial. I want to have the right trial size... but most importantly, I need to make sure that I have strong data throughout a series of subpopulations that will be important for the future label." — Dean Y. Li
"At this time, we have not spoken about communication plans following IA. But, you know, we are excited about this first-in-class, once-per-season, strain-agnostic antiviral agent, which I think will have increasing need as the years go by." — Dean Y. Li

Strategy and Ambition for sacTMT (TROP‑2 ADC) – “Conservative” vs “Workhorse” Program, Biomarkers, and Positioning

Sentiment: Mixed

"We think sac TMT has the potential to be best in class trope two-directed ADCs... we have 16 phase three studies, 11 that we view are first in class. The other five are differentiated. So I just I think we are very ambitious with our SACTMT program... I would challenge a little bit the characterization that we do not have a robust and ambitious program." — Dean Y. Li
"There will be tumor types where we do not believe that a biomarker will be needed, but we also believe that there are places where that biomarker will be needed, especially if you look at how good the comparator you have to go against... a lot of it is context-dependent on the tumor, but also what other treatments are there and how high of a bar you have to beat." — Dean Y. Li

WINREVAIR (Winravir) – Durability, Real‑World Use, and Expansion into Additional Pulmonary/Right‑Heart Indications

Sentiment: Positive

"WinRevir is reshaping the standard of care in PAH. It is doing it because it is a differentiated pathway and a molecule... the way that I would actually begin to think about winravir... is similar to what Merck showed for ACE inhibitors back in the day in relationship to left heart failure." — Dean Y. Li
"We have over 110,000 prescriptions which have been dispensed. There are now over 9,100 patients who have started therapy... our overall compliance continues to be quite high... we continue to be very confident in the safety profile, and it is consistent with the label." — Robert M. Davis

Bull Case

A broadened, increasingly de-risked pipeline across oncology, cardiometabolic, infectious disease, HIV, immunology, and ophthalmology, combined with disciplined but active BD, enables Merck to offset KEYTRUDA LOE and sustain mid-single-digit or better growth into the 2030s.

Bear Case

Despite a large stated $70B opportunity, Merck faces a period of muted reported growth, major LOE and IRA headwinds, intense competition in key pipeline categories, and potential pressure to pursue large acquisitions that could dilute returns and heighten execution risk.

Looking Ahead

Investors will be closely watching Merck & Co.'s next quarterly report for continued execution, particularly around durability of KEYTRUDA’s IP/LOE and Role of QLEX in Managing the Cliff. With operating margins at 53.3%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Merck & Co.'s revenue in Q4 2025?

Merck & Co. reported Q4 2025 revenue of $16.4B, representing a +5.0% year-over-year change.

Did Merck & Co. beat earnings expectations in Q4 2025?

The stock rose +2.2% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: A broadened, increasingly de-risked pipeline across oncology, cardiometabolic, infectious disease, HIV, immunology, and ophthalmology, combined with disciplined but active BD, enables Merck to offset KEYTRUDA LOE and sustain mid-single-digit or better growth into the 2030s.

What is the bull case for MRK stock?

The bull case for MRK centers on: A broadened, increasingly de-risked pipeline across oncology, cardiometabolic, infectious disease, HIV, immunology, and ophthalmology, combined with disciplined but active BD, enables Merck to offset KEYTRUDA LOE and sustain mid-single-digit or better growth into the 2030s.

What is the bear case for MRK stock?

The bear case for MRK centers on: Despite a large stated $70B opportunity, Merck faces a period of muted reported growth, major LOE and IRA headwinds, intense competition in key pipeline categories, and potential pressure to pursue large acquisitions that could dilute returns and heighten execution risk.

How has MRK stock performed since its Q4 2025 earnings?

MRK moved +2.2% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +35.5% since earnings. Year-to-date, the stock has returned +16.3%.

Browse all 400+ earnings reports →

Learn More

Analyze MRK in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Merck & Co. and 400+ other stocks, explore the full platform.

Open MRK on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.